Clin Infect Dis by Cleveland, Angela Ahlquist et al.
Changes in Incidence and Antifungal Drug Resistance in 
Candidemia: Results From Population-Based Laboratory 
Surveillance in Atlanta and Baltimore, 2008–2011
Angela Ahlquist Cleveland1, Monica M. Farley2, Lee H. Harrison3, Betsy Stein2, Rosemary 
Hollick3, Shawn R. Lockhart1, Shelley S. Magill4, Gordana Derado1, Benjamin J. Park1, and 
Tom M. Chiller1
1Mycotic Diseases Branch, Division of Foodborne, Waterborne and Environmental Diseases, 
Centers for Disease Control and Prevention, Atlanta 2Georgia Emerging Infections Program, 
Atlanta Veterans Affairs Medical Center and Emory University, Georgia 3Department of 
International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 
4Surveillance Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and 
Prevention, Atlanta, Georgia
Abstract
Background—Candidemia is common and associated with high morbidity and mortality; 
changes in population-based incidence rates have not been reported.
Methods—We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, 
and Baltimore City/County, Maryland (combined population 5.2 million), during 2008–2011. We 
calculated candidemia incidence and antifungal drug resistance compared with prior surveillance 
(Atlanta, 1992–1993; Baltimore, 1998–2000).
Results—We identified 2675 cases of candidemia with 2329 isolates during 3 years of 
surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 
in Baltimore. Rates were highest among adults aged ≥65 years (Atlanta, 59.1; Baltimore, 72.4) and 
infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior 
surveillance, adjusted incidence significantly declined for infants of both black and white race 
(Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17–.38]; white RR: 0.19 
[95% CI, .12–.29]; Baltimore: black RR, 0.38 [95% CI, .22–.64]; white RR: 0.51 [95% CI: .29–.
90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 
32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant 
to both fluconazole and an echinocandin.
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Conclusions—We describe marked shifts in candidemia epidemiology over the past 2 decades. 
Adults aged ≥65 years replaced infants as the highest incidence group; adjusted incidence has 
declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, 
or changes in catheter insertion practices may be contributing to these declines. Further 
surveillance for antifungal resistance and efforts to determine effective prevention strategies are 
needed.
Bloodstream infections (BSIs) caused by Candida species, also known as candidemia, are an 
important public health problem in the United States. Candida species are among the most 
common causes of BSIs and are associated with high morbidity and mortality, as well as 
increases in hospital cost and length of stay [1–5].
Although most reports that describe the epidemiology of candidemia are from individual 
institutions or among specific patient groups, few reports in the United States have described 
the epidemiology of candidemia at a population level. Population-based data are important 
for describing infections in whole populations and across the entire spectrum of healthcare 
settings, and can be used to determine group-specific incidence rates to monitor and 
compare rates of infection over time. Previous population-based surveillance performed by 
the Centers for Disease Control and Prevention (CDC) and partners in Atlanta, Georgia 
(1992–1993), and Baltimore, Maryland (1998–2000), described incidence rates of 8.7 per 
100 000 population in Atlanta and 24 per 100 000 population in Baltimore [6, 7]. During 
both surveillance periods, drug resistance to fluconazole was low: 3% of isolates were 
resistant in 1992, and 3.7% were resistant in 1998 [6–8].
Over the past decade, Candida species with reduced fluconazole susceptibility, such as 
Candida glabrata, have become more prevalent in some patient populations [8–12]. The 
newest class of antifungal medications, the echinocandins, are considered first-line empiric 
therapy for candidemia, and there are reports of echinocandin-resistant invasive infection 
[13, 14].
To evaluate changes in the epidemiology and antifungal drug resistance of candidemia, we 
conducted population-based prospective surveillance in metropolitan Atlanta, Georgia, and 
Baltimore City and County, Maryland, 2 areas where prior surveillance had been conducted.
MATERIALS AND METHODS
Surveillance Population
Surveillance for candidemia was conducted among residents of Atlanta, Georgia (Fulton, 
DeKalb, Cobb, Gwinnett, Clayton, Douglas, Newton, and Rockdale counties; 25 hospitals, 
population: 3.8 million) and Baltimore City and County, Maryland (14 hospitals, population: 
1.4 million). Each catchment area is the same as prior surveillance (Atlanta, 1992–1993 [6]; 
Baltimore, 1998–2000 [7]).
Case Definitions
We defined an incident case of candidemia as the first blood culture positive for a Candida 
species collected from a resident of the surveillance area. An episode of candidemia was 
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defined by the 30-day period following the day of collection of the incident blood culture. 
Blood cultures with Candida collected >30 days after the incident blood culture were 
defined as new incident cases.
Candidemia episodes were categorized as hospital-onset (HO), healthcare-associated 
community-onset (HACO), or community-onset (CO). Hospital-onset candidemia was 
defined as candidemia occurring in patients whose incident blood cultures were collected on 
or after the third day of hospital admission, where admission date is the first day. 
Candidemia episodes obtained before the third day of hospital admission were categorized 
as either HACO or CO: candidemia episodes in patients with recent healthcare exposure 
were categorized as HACO if the patient (1) was a resident of a nursing home at the time of 
culture collection; (2) had a central venous catheter in place 2 days before, the day before, or 
on the day of culture collection; (3) had documentation of at least 1 of the following in the 
90 days prior to candidemia: hospitalization, surgery, or hemodialysis; (4) was transferred 
from another acute care hospital; or (5) was a neonate (aged ≤30 days) at the time of 
candidemia, Patients without any of these criteria were classified as CO.
Data Collection
Surveillance data were collected for 3 years at each location (1 March 2008–28 February 
2011 in Atlanta; 1 June 2008–31 May 2011 in Baltimore). Basic demographic and clinical 
information was collected on all cases, and additional clinical information (referred to as 
“enhanced surveillance”) on antifungal treatment and severity of illness was collected for 
the first 2 years of surveillance in each location (1 March 2008–28 February 2010 in 
Atlanta; 1 June 2008–31 May 2010 in Baltimore). Surveillance personnel used standardized 
case report forms to abstract data from medical records. Laboratory records from all 
participating laboratories were audited monthly, ensuring complete capture of all cases.
Isolate Collection, Identification, and Antifungal Susceptibility Testing
All available isolates were sent to the CDC for species confirmation and antifungal drug 
susceptibility testing. Isolates were identified using a Luminex assay or DNA sequencing of 
the D1-D2 subunit of the 28S recombinant DNA [15]. CDC-confirmed species are reported; 
if no isolate was received at the CDC, local laboratory species identifications are reported.
Antifungal susceptibility testing was performed by broth microdilution with fluconazole, 
itraconazole, voriconazole, posaconazole, flucytosine, anidulafungin, caspofungin, and 
micafungin as described by Clinical and Laboratory Standards Institute (CLSI) M27-A3 
guidelines [16] using frozen RPMI microbroth trays (TREK Diagnostics, Cleveland, Ohio). 
We used the recently approved, species-specific CLSI 24-hour resistance breakpoints for 
fluconazole, voriconazole, and echinocandins [16]. Isolates of Candida krusei were 
considered intrinsically resistant to fluconazole. Amphotericin B susceptibility was 
performed using Etest as per the manufacturer’s instructions (bioMérieux, Durham, North 
Carolina); minimum inhibitory concentration values were read at 24 hours. Where 
comparisons were made to previous surveillance data [6, 7] the new breakpoints were 
applied to the old data [16], and thus resistance reported here differs from resistance 
previously reported. The testing protocols do not differ.
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Statistical Methods and Denominators
All incidence rates were calculated using 2009 population estimates for Baltimore [17] and 
Atlanta [18] and are presented per 100 000 person-years. We used original case and isolate 
data to calculate incidence rates in Atlanta (1992–1993) [6] and Baltimore (1998–2000) [7]. 
Owing to inconsistency between Atlanta denominators obtained from the 1990 US census 
and prior published data, our reported 1992–1993 Atlanta rates are slightly higher than 
previously reported [6].
We report crude rates to describe the burden in the current population, as well as adjusted 
rates to describe changes over time. For adjusted rates, the data were first aggregated by 
several factors: time period, age group, race, sex, and species. Negative binomial regression 
models were then fit to the data to examine the relationship between those factors and the 
candidemia incidence rates, and to evaluate the change in average annual incidence rates 
between the 2 time periods. To assess the goodness of fit of a proposed model, we compared 
observed and expected rates under the assumed model. We found evidence of effect 
modification by age and race, and thus report group-specific relative risks to summarize 
changes in incidence over time. Patients with missing race data (<4% of all patients) were 
removed from multivariate modeling analyses.
Categorical variables were analyzed using χ2 tests or Fisher exact tests. We used the Kaplan-
Meier method to describe survival 30 days after incident candidemia. In all analyses, the 
level of significance was set at α = .05.All analyses were done using SAS software (version 
9.3; SAS Institute, Cary, North Carolina).
Human Subjects
The CDC conducted ethical review of this surveillance project and deemed it a nonresearch 
activity; therefore, it was not subject to review by a CDC institutional review board. This 
activity was also evaluated individually at each location, and was either deemed a public 
health assessment or human subjects research and was approved by local review boards.
RESULTS
Demographic and Clinical Characteristics
We identified 2675 cases of candidemia in Atlanta and Baltimore during the 3-year 
surveillance period (Table 1). The median age of patients was 58 years (interquartile range 
[IQR], 45–71 years), and 51% were male; 217 patients (8%) had >1 episode of candidemia. 
The most common underlying conditions documented within the 3 months prior to 
candidemia were surgery (36%), diabetes (34%), and malignancy (21%). Most patients (n = 
2265 [85%]) had a central venous catheter (CVC) in place within 2 days prior to incident 
candidemia, and of those, 1612 (71%) had all CVCs removed within 7 days of incident 
candidemia.
Most patients (n = 1775 [66%]) had infection occur during hospitalization (HO), or upon 
admission with documented exposures to healthcare (HACO; n = 787 [29%]); only 113 
patients (4%) lacked recent documented healthcare exposure (CO, Table 1). Among the 787 
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HACO patients, 642 (82%) had documentation of a CVC within 2 days prior to or on the 
day of initial culture. CO patients were older than other patients (median age, 68 years vs 58 
years in non-CO; P < .001), and more likely to have diabetes (39% vs 33% in non-CO; P < .
001); C. glabrata was most frequently isolated in this group (n = 45 [40% of all species 
found in CO patients]), followed by Candida albicans (n = 36 [32%]) and Candida 
parapsilosis (n = 15 [13%]).
Enhanced Surveillance Results
During the 2 years of enhanced surveillance, we identified 1863 patients with candidemia. A 
total of 1143 patients (61%) were in an intensive care unit (ICU) within the 14 days before 
or after candidemia (Table 1). Among adult (aged ≥18 years) patients (n = 1749), 1333 
(76%) met criteria for sepsis [19].
Antifungal medication data were available for 1807 patients (97% of 1863 patients) during 
the 2-year enhanced surveillance period, of whom 1616 (89%) received an antifungal 
following candidemia (Table 1); fluconazole (n = 1245 [77%]) or an echinocandin (n = 988 
[61%]) was most commonly administered, and median treatment duration was 12 days 
(IQR, 6–17 days). For initial therapy, patients first received fluconazole (n = 938 patients 
[52%]) or micafungin (n = 371 [20%]). Most patients (n = 857 [53%]) received >1 
antifungal. Among those who did not receive antifungal treatment (n = 191 [10%]), most (n 
= 109 [57%]) died or were discharged before the culture result was available to the clinician. 
A total of 278 patients (15%) had received an antifungal medication in the 14 days prior to 
candidemia; fluconazole was the most common choice (n = 177 [64%]), followed by an 
echinocandin (n = 41 [15%]).
Changes in Incidence Rates and Mortality
The average annual crude incidence rate per 100 000 person-years during 2008–2011 was 
13.3 in Atlanta and 26.2 in Baltimore (Table 1). Rates were highest among persons aged ≥65 
years (59.1 in Atlanta, 72.4 in Baltimore), persons <1 year of age (34.3 in Atlanta, 46.2 in 
Baltimore), and persons of black race (20.5 in Atlanta, 33.8 in Baltimore; Figure 1).
Although compared to prior surveillance periods overall crude incidence was 46% higher in 
Atlanta and 8% higher in Baltimore (Table 1), changes in rates varied by age group and 
race. Age- and race-specific strata illustrate variability in these differences between the 2 
reporting sites (Figure 1). In both locations, rates significantly declined for all persons <20 
years of age (Figure 2). Among persons aged ≥20 years, changes varied by location: In 
Atlanta, changes in incidence among persons aged ≥20 years were significant for all black 
persons aged ≥20 years and in all white persons aged ≥45, whereas in Baltimore, rates in 
persons aged ≥20 years changed little compared to prior surveillance, except for a slight 
increase in risk among white persons aged 45–64 years (Figure 2).
Thirty-day case fatality decreased significantly since 1998–2000 in Baltimore (28% in 
2008–2011 vs 50% in 1998–2000, P < 0.001), but was similar between the 2 time periods 
for Atlanta (29% in 2008–2011 vs 35% in 1992–1993 P = .09).
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Candida Species and Antifungal Susceptibility
Among 2675 total cases, the CDC received 2329 isolates from 2227 patients (83% of total 
cases); 99 patients (4%) had >1 isolate of different species available for testing, and 448 
patients (17%) had no isolate. Incident isolates were available for 2136 (80%) patients. 
When species identifications from submitting laboratories were compared to CDC results, 
107 isolates (5%) were discrepant (results not shown).
Species distributions and antifungal resistance testing results of the isolates received at the 
CDC are shown in Table 2. Among all isolates received at the CDC, C. albicans was the 
most common species (n = 877 [38%]), followed by C. glabrata (n = 670 [29%]), C. 
parapsilosis (n = 389 [17%]), and Candida tropicalis (n = 241 [10%]; Table 2).
Compared with prior surveillance, changes in species-specific incidence rates varied by 
location and age group (Table 3). In Atlanta, in persons aged ≥20 years, the risk for almost 
all Candida species increased compared with prior surveillance (Table 3); the increase was 
greatest in non–C. albicans species, particularly for C. glabrata and C. parapsilosis 
(increase in risk varied by age group; Table 3). In Baltimore, changes were less robust and 
limited to increases in C. parapsilosis in 2 of the 5 age groups (Table 3). In both locations, 
C. albicans decreased among all persons aged <20 years.
Overall, 165 isolates (7%) were resistant to fluconazole (Table 2). Thirty-one isolates (1%) 
were resistant to an echinocandin antifungal; the majority (n = 20 [65%]) were C. glabrata. 
Eight of the 9 isolates resistant to both an echinocandin and fluconazole were C. glabrata.
DISCUSSION
This report describes the largest prospective, population-based surveillance for candidemia 
in the United States and is the first to compare changes in the incidence of candidemia over 
time in large metropolitan areas. Importantly, we report substantial shifts in the 
epidemiology of candidemia among specific age groups. Infants, who previously had the 
highest incidence rates of all high risk groups, are now second to adult patients aged ≥65 
years, and non–C. albicans species now comprise two-thirds of all Candida species isolated 
in blood.
Neonates and infants have historically been populations with some of the highest rates of 
candidemia [3, 6, 7, 20–23]. Although infants aged <1 year still have high rates, we 
observed a significant decline in incidence in this group compared to prior surveillance. This 
decline is consistent with other reports [21, 24]. We also observed a decline in incidence 
among infants aged <1 year in both locations during the 3 years of surveillance (results not 
shown). Prophylaxis with fluconazole in high-risk patients, such as neonates, has been 
shown to decrease risk of disease [21, 25–29]. However, it is unknown if the declines in 
neonatal candidemia have occurred only because of the increased use of azoles as 
prophylaxis in neonatal ICUs. Declines were also seen in other pediatric populations, and 
the possible contributions of improved infection control practices, such as hand hygiene and 
catheter care, deserve further study.
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Persons aged ≥65 are now the highest-risk group for candidemia in both areas under 
surveillance. The shift in burden from neonates to adults is a major finding of this report. 
The reasons for the changing incidence are likely multifactorial; some contribution may be 
due to changes in the prevalence of risk factors in the adult population. Increases in common 
risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving 
immunosuppressive therapies [33] may have resulted in increases in the overall pool of 
patients at high risk for candidemia. Additionally, we report that CO patients were older and 
more likely to have diabetes than other patients. Thus, persons without recent healthcare 
exposures but with other chronic health conditions that are risk factors for candidemia may 
also be contributing to the increase in incidence in this age group.
Recent reports have documented significant and dramatic declines in some central line–
associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus, following 
adherence to established central line insertion practices; however, similar dramatic declines 
have been less evident for CLABSIs due to Candida species [20, 24, 34–36]. Candida 
species are commensals of the human gastrointestinal tract and can cause BSIs that are not 
the direct result of poor central line insertion practices, and instead may be more dependent 
on catheter maintenance after insertion [20, 22, 34] or may be unrelated to the central line. 
Therefore, interventions to reduce CLABSIs that focus solely on line insertion practices may 
be less effective in preventing candidemia. Further research is needed to define the 
proportion of candidemias that are central line related, and to identify catheter care strategies 
effective in preventing candidemia.
Over the past 20 years, the emergence of non–C. albicans species has been well documented 
[20, 37–42]. Our surveillance confirms these reports; non–C. albicans species now comprise 
two-thirds of all candidemias in Atlanta and in Baltimore City/County. We report little 
change among the overall proportion of isolates that were resistant to fluconazole; however, 
we also report an increase among some groups in the incidence of candidemia due to species 
with reduced fluconazole susceptibility, such as C. glabrata. As C. glabrata comprised more 
than half of the isolates resistant to 1 of the 2 drug classes (azoles and echinocandins), and 8 
of the 9 isolates resistant to both classes, it is important to monitor this particular species for 
drug resistance. Additionally, echinocandin antifungals are a new class of drugs introduced 
in the past decade. Although the low overall level of resistance to echinocandins reported 
here is reassuring, especially among species like C. parapsilosis, it will also be important to 
monitor for the emergence of echinocandin resistance as this drug class is now first-line 
empiric therapy for candidemia.
This surveillance was subject to several limitations. Large medical centers in each 
metropolitan area contributed the most cases to the surveillance population, and the overall 
epidemiology in each area was influenced by the epidemiology in these centers. Thus, these 
data may not be nationally representative. However, they do represent one of the largest 
populations evaluated for changes in incidence of candidemia in the United States. The 
differences described in the epidemiology between the 2 locations surveyed emphasize the 
geographic and demographic variability of candidemia; surveillance in additional 
geographic areas will be important to further describe the epidemiology of this infection. We 
were unable to identify patients who received care outside the catchment area or from 
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healthcare facilities that sent blood cultures to labs outside of the catchment area, and were 
unable to collect isolates from one major federal institution. For these reasons, we may have 
underestimated the burden of disease in these areas.
This report demonstrates that the overall incidence of candidemia and the burden in adult 
populations has not declined in the past 20 years, and emphasizes the significant morbidity 
and mortality that candidemia contributes to the healthcare system. The changing face of 
healthcare is likely leading to growing populations of persons at risk for the development of 
candidemia. Our ability to prevent significant morbidity and mortality from candidemia 
remains a challenge. Although antifungal prophylaxis has been shown to be effective in 
selected patient populations, there is still debate on the application of risk prediction tools 
[43] and other preventive strategies. There is a continued need for surveillance of 
candidemia to develop and evaluate prevention strategies and to monitor for changes in 
incidence and resistance.
Acknowledgments
We gratefully acknowledge the many individuals in the hospitals and laboratories in Baltimore and Atlanta for their 
help in identifying cases and isolates, and also thank the following individuals: Wendy Baughman, MSPH, Janine 
Ladson, MPH, Lewis Perry, RN, MPH, Georgia Emerging Infections Program; Sandra Muhanuka, MPH, Helen 
Yoon, MS, Carolyn Kreiner, MS, RN, Debbie Lundy, BSN, Kim Holmes, RN, MS, Kathleen Shutt, MS, Maryland 
Emerging Infections Program; Scott Fridkin, MD, Yi Mu, PhD, Jonathan Edwards, MStat, Division of Healthcare 
Quality Promotion; Kaitlin Benedict, MPH, Randy Kuykendall, MPH, Shirley McClinton, Joyce Peterson, Carol 
Bolden, Naureen Iqbal, Lalitha Gade, Kizee Etienne, MPH, and Mary Brandt, PhD, Mycotic Diseases Branch.
References
1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial 
bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide 
surveillance study. Clin Infect Dis. 2004; 39:309–17. [PubMed: 15306996] 
2. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable 
outcomes of candidemia in adults and children hospitalized in the United States: a propensity 
analysis. Clin Infect Dis. 2005; 41:1232–9. [PubMed: 16206095] 
3. Fridkin SK. Candidemia is costly—plain and simple. Clin Infect Dis. 2005; 41:1240–1. [PubMed: 
16206096] 
4. Morgan JMD, Meltzer MIP, Plikaytis BDM, et al. Excess mortality, hospital stay, and cost due to 
candidemia: a case-control study using data from population-based candidemia surveillance. Infect 
Control Hosp Epidemiol. 2005; 26:540–7. [PubMed: 16018429] 
5. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, 
revisited. Clin Infect Dis. 2003; 37:1172–7. [PubMed: 14557960] 
6. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: 
results of a population-based active surveillance. Clin Infect Dis. 1999; 29:1164–70. [PubMed: 
10524958] 
7. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida 
species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based 
active surveillance program. J Clin Microbiol. 2004; 42:1519–27. [PubMed: 15070998] 
8. Pfaller MA, Messer SA, Hollis RJ, et al. Trends in species distribution and susceptibility to 
fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol 
Infect Dis. 1999; 33:217–22. [PubMed: 10212747] 
9. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, et al. Risk factors for fluconazole-resistant 
candidemia. Antimicrob Agents Chemother. 2010; 54:3149–54. [PubMed: 20498325] 
Cleveland et al. Page 8













10. Klevay MJ, Ernst EJ, Hollanbaugh JL, Miller JG, Pfaller MA, Diekema DJ. Therapy and outcome 
of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis. 
2008; 60:273–7. [PubMed: 18024053] 
11. Ortega M, Marco F, Soriano A, et al. Candida spp. bloodstream infection: influence of antifungal 
treatment on outcome. J Antimicrob Chemother. 2010; 65:562–8. [PubMed: 20083551] 
12. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for 
resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004; 42:4419–
31. [PubMed: 15472288] 
13. Lewis RE. Trends in invasive Candida infections and their treatment: focus on echinocandins. Curr 
Med Res Opin. 2009; 25:1729–62.
14. Garcia-Effron G, Chua DJ, Tomada JR, et al. Novel FKS mutations associated with echinocandin 
resistance in Candida species. Antimicrob Agents Chemother. 2010; 54:2225–7. [PubMed: 
20145084] 
15. Deak E, Etienne KA, Lockhart SR, Gade L, Chiller T, Balajee SA. Utility of a Luminex-based 
assay for multiplexed, rapid species identification of Candida isolates from an ongoing 
candidemia surveillance. Can J Microbiol. 2010; 56:348–51. [PubMed: 20453902] 
16. Institute CaLS. M27-A3 Reference method for broth dilution antifungal susceptibility testing of 
yeasts: approved standard—third edition. Clinical Laboratory Standards Institute; Wayne, PA: 
2008. 
17. Maryland Vital Statistics Annual Report 2009. Division of Health Statistics, Maryland Department 
of Health and Mental Hygiene. 2009
18. National Center for Health Statistics. Estimates of the 1 July 2000–1 July 2009, United States 
resident population from the Vintage 2009 postcensal series by year, county, age, sex, race, and 
Hispanic origin. Prepared under a collaborative arrangement with the U.S. Census Bureau. 2009. 
Available at: http://www.cdc.gov/nchs/nvss/bridged_race.htm. Accessed 1 December 2012
19. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the 
use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. 
American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 10:1644–
55. [PubMed: 1303622] 
20. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health 
problem. Clin Microbiol Rev. 2007; 20:133–63. [PubMed: 17223626] 
21. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida 
bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics. 2006; 
117:1680–7. [PubMed: 16651324] 
22. Chang A, Neofytos D, Horn D. Candidemia in the 21st century. Future Microbiol. 2008; 3:463–72. 
[PubMed: 18651817] 
23. Shetty SS, Harrison LH, Hajjeh RA, et al. Determining risk factors for candidemia among newborn 
infants from population-based surveillance: Baltimore, Maryland, 1998–2000. Pediatr Infect Dis J. 
2005; 24:601–4. [PubMed: 15999000] 
24. Schulman J, Stricof R, Stevens TP, et al. Statewide NICU central-line-associated bloodstream 
infection rates decline after bundles and checklists. Pediatrics. 2011; 127:436–44. [PubMed: 
21339265] 
25. Burwell LA, Kaufman D, Blakely J, Stoll BJ, Fridkin SK. Antifungal prophylaxis to prevent 
neonatal candidiasis: a survey of perinatal physician practices. Pediatrics. 2006; 118:e1019–26. 
[PubMed: 16982807] 
26. Pappas P, Kauffman C. Clinical practice guidelines for the management of candidiasis: 2009 
update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503–35. [PubMed: 
19191635] 
27. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in 
preterm neonates. N Engl J Med. 2007; 356:2483–95. [PubMed: 17568029] 
28. Kaufman DA. Fluconazole prophylaxis: can we eliminate invasive Candida infections in the 
neonatal ICU? Curr Opin Pediatr. 2008; 20:332–40. [PubMed: 18475105] 
Cleveland et al. Page 9













29. Kaufman D. Fluconazole prophylaxis decreases the combined outcome of invasive Candida 
infections or mortality in preterm infants. Pediatrics. 2008; 122:1158–9. author reply 1159. 
[PubMed: 18978001] 
30. Boyle J, Thompson T, Gregg E, Barker L, Williamson D. Projection of the year 2050 burden of 
diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes 
prevalence. Popul Health Metr. 2010:8, 29. [PubMed: 20429875] 
31. Lerolle N, Trinquart L, Bornstain C, et al. Increased intensity of treatment and decreased mortality 
in elderly patients in an intensive care unit over a decade. Crit Care Med. 2010; 38:59–64. 
[PubMed: 19633539] 
32. Halpern NA, Pastores SM. Critical care medicine in the United States 2000–2005: an analysis of 
bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010; 38:65–71. [PubMed: 
19730257] 
33. OPTN/SRTR 2010 Annual Data Report. Department of Health and Human Services, Health 
Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. 
Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant 
Recipients (SRTR); Rockville, MD: 2011. 
34. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related 
bloodstream infections in the ICU. New Engl J Med. 2006; 355:2725–32. [PubMed: 17192537] 
35. Marcos M, Soriano A, Iñurrieta A, et al. Changing epidemiology of central venous catheter-related 
bloodstream infections: increasing prevalence of gram-negative pathogens. J Antimicrob 
Chemother. 2011; 66:2119–25. [PubMed: 21665905] 
36. Centers for Disease Control and Prevention. Vital signs: central line-associated blood stream 
infections—United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep. 2011; 60:243–
8. [PubMed: 21368740] 
37. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-
Candida albicans species and antifungal resistance. Am J Med. 1996; 100:617–23. [PubMed: 
8678081] 
38. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive 
candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in 
hematologic malignancy. Cancer. 2008; 112:2493–9. [PubMed: 18412153] 
39. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections 
Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive 
care unit patients in the United States during 1989–1999. Clin Infect Dis. 2002; 35:627–30. 
[PubMed: 12173140] 
40. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-
albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a 
systematic review. Int J Infect Dis. 2010; 14:e954–66. [PubMed: 20797887] 
41. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida spp. 
distribution and antifungal resistance rates among bloodstream infection isolates by patient age: 
report from the SENTRY Antimicrobial Surveillance Program (2008–2009). Diagn Microbiol 
Infect Dis. 2010; 68:278–83. [PubMed: 20846808] 
42. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic variation in the frequency of isolation and 
fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the 
ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis. 2010; 
67:162–71. [PubMed: 20338711] 
43. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, et al. Early treatment of candidemia in adults: a 
review. Med Mycol. 2011; 49:113–20. [PubMed: 20818922] 
Cleveland et al. Page 10














A comparison of crude average annual incidence rates per 100 000 persons in Atlanta 
(1992–1993 vs 2008–2011) and Baltimore (1998–2000 vs 2008–2011), overall, and by sex, 
race, and age group.
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A comparison of adjusted incidence rate ratios, by age group and race, comparing rates in 
the previous time period (1992–1993 in Atlanta, 1998–2000 in Baltimore) to rates in the 
current time period (2008–2011). 95% confidence interval. The line represents a relative risk 
of 1. Rates to the right of the line are an increase in risk compared to prior surveillance; rates 
to the left of the line are a decrease in risk compared to prior surveillance. Abbreviations: 
CI, confidence interval; RR, relative risk.
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Table 1
Selected Demographic and Clinical Characteristics of Persons With Candidemia in Atlanta and Baltimore 
(Comparison of Prior Surveillance With Current Surveillance Data)











Crude incidence rate (per 100 000 person-years) 9.1 13.3 24.2 26.2
Sex
a
 Female 173 (40) 748 (48) 328 (48) 540 (48)
 Male 253 (59) 806 (52) 352 (52) 579 (52)
Race
a
 White 175 (41) 525 (34) 260 (38) 447 (40)
 Black 193 (45) 929 (60) 406 (60) 623 (56)
Median age, years (IQR) 46 (6–69) 58 (44–70) 57 (40–73) 58 (45–72)
Age (years)
a
 <1 85 (20) 61 (4) 39 (6) 27 (2)
 1–19 35 (8) 62 (4) 34 (5) 18 (2)
 20–44 85 (20) 271 (17) 143 (21) 230 (21)
 45–64 92 (21) 598 (38) 198 (29) 428 (38)
 ≥65 129 (30) 562 (36) 265 (39) 411 (37)
Underlying or prior conditions
 Surgery in the 3 months prior
b 80 (19) 588 (38) 319 (47) 366 (33)
  Abdominal surgery 54 (13) 367 (24) 178 (26) 222(20)
  Nonabdominal surgery 26 (6) 312 (20) NA 201 (18)
 Diabetes 55 (13) 508 (33) 193 (28) 392 (35)
 Malignancies 113 (26) 339 (22) 145 (51) 212 (19)
 Renal conditions NA 250 (16) 202 (30) 203 (18)
 Liver diseases 9 (2) 126 (8) 108 (16) 199 (18)
 HIV or AIDS 29 (7) 55 (4) 72 (11) 95 (8)
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Central venous catheter usage
 CVC at time of candidemia NA 1342 (86) 520 (76) 923 (82)




 Candidemia ≤2 days after admission or no admission
110 (28)
d 443 (29) 229 (34) 461 (41)
Acquisition of candidemia
 Hospital onset NA 1114 (72) NA 661 (59)
 Health care-associated community-onset NA 386 (25) NA 401 (36)
 Community-onset NA 54 (3) NA 59 (5)
Severity of illness
 Crude 30-day all-cause mortality
e 35% 29% 50% 28%
 Had >1 episode of candidemia 18 (4) 99 (6) 33 (3) 118 (11)
 SIRS at time of candidemia (age ≥18 years only)
f NA 798 (81) NA 535 (70)
 In ICU within 14 days before or after candidemia
f NA 756 (49) NA 494 (44)
 In ICU at time of candidemia
f NA 508 (33) 218 (32) 333 (30)
Treatment
f
 Treatment information available NA 1052 (98) NA 755 (95)
 Received antifungals in the 14 days prior to candidemia NA 195 (18) NA 83 (10)
 Received antifungals after candidemia NA 956 (90) NA 660 (83)
Species
g
  C. albicans 223 (52) 629 (40) 289 (43) 369 (33)
 Non-C. albicans 205 (48) 925 (60) 391 (58) 752 (67)
    C. glabrata 51 (12) 403 (26) 188 (28) 325 (29)
    C. tropicalis 43 (10) 129 (8) 14 (98) 131 (12)
    C. parapsilosis 90 (21) 262 (17) 72 (11) 172 (15)
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Data are number (%) of all cases unless otherwise indicated.
Abbreviations: CVC, central venous catheter; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range; NA, not 
applicable as question was not asked in surveillance time period; SIRS, systemic inflammatory response syndrome.
a
Some variables could not be collected for every case.
b
Patients could have >1 type of surgery.
c
Question in 1998–2000 was: “Was CVC removed or changed after diagnosis of candidemia?”
d
A total of 386 patients had admission information available in 2008–2010.
e
Crude 30-day all-cause mortality calculated using Kaplan-Meier method.
f
Data collected in 2 years of enhanced surveillance.
g
Species are reported per patient. In cases where no isolate was available to be sent to the Centers for Disease Control and Prevention, local lab 
identification is used.
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Table 2
Candida Species Distribution and Antifungal Resistance to Fluconazole and Echinocandins of Total Isolates 
Received at the Centers for Disease Control and Prevention, 2008–2011, Compared With Prior Surveillance in 
Atlanta and Baltimore






























C. albicans 1 (1) 11 (2) 5 (1) 489 (41) 8 (3) 9 (2) 1 (0) 388 (34)
Non–C. albicans 15 (12) 83 (12) 10 (1) 709 (59) 32 (10) 62 (9) 15 (2) 743 (66)
  C. glabrata 7 (20) 42 (13) 10 (3) 318 (27) 12 (8) 38 (11) 10 (3) 352 (31)
  C. tropicalis 1 (3) 9 (9) 0 (0) 103 (9) 7 (9) 6 (4) 3 (2) 138 (12)
  C. parapsilosis 1 (2) 12 (6) 0 (0) 212 (18) 0 (0) 4 (2) 1 (1) 177 (16)
  C. krusei 0 (0) 19 (100) 0 (0) 19 (2) 0 (0) 13 (100) 0 (0) 13 (1)
  C. dubliniensis 0 (0) 1 (20) 0 (0) 5 (<1) 0 (0) 1 (3) 1 (3) 31 (3)
  C. lusitaniae 0 (0) 0 (0) 0 (0) 22 (2) 0 (0) 0 (0) 0 (0) 12 (1)
Other species 0 (0) 0 (0) 0 (0) 30 (3) 0 (0) 0 (0) 0 (0) 20 (2)
All species 16 (7) 94 (8) 15 (1) 1198 (100) 40 (7) 71 (6) 16 (1) 1131 (100)
Data are No. (%) of all isolates by Candida species resistant to either fluconazole or an echinocandin antifungal drug, and overall No. (%) of all 
isolates, by location and time period.
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Table 3
Changes in Candida Species, by Age Group: Comparison of Rates in the Previous Time Period (1992–1993 in 









(95% CI)Species by Age Group 1992–1993 2008–2011 1998–2000 2008–2011
<1 year
  C. albicans 66.82 17.44 0.26 (.16–.42)* 70.70 19.86 0.28 (.14–.58)*
  C. glabrata 0.00 3.61 … 12.29 7.22 0.59 (.15–2.35)
  C. parapsilosis 39.11 7.22 0.18 (.09–.37)* 27.66 12.64 0.46 (.17–1.23)
 Other Candida spp 6.52 3.01 0.46 (.12–1.72) 6.15 5.42 0.88 (.15–5.27)
1–19 years
  C. albicans 1.06 0.59 0.23 (.11–.47)* 2.19 0.51 0.23 (.08–.64)*
  C. glabrata 0.25 0.61 2.49 (.62–9.96) 0.44 0.20 0.46 (.08–2.78)
  C. parapsilosis 1.14 0.43 0.37 (.18–.80)* 0.29 0.41 1.39 (.26–7.62)
 Other Candida spp 0.25 0.40 1.61 (.46–5.72) 2.04 0.61 0.30 (.11–.78)*
20–44 years
  C. albicans 1.85 2.56 1.38 (.96–1.99) 6.31 4.98 0.79 (.56–1.11)
  C. glabrata 0.38 3.80 10.01 (4.77–21.01)* 4.24 3.25 0.77 (.50–1.16)
  C. parapsilosis 0.47 1.13 2.37 (1.20–4.69)* 1.03 2.63 2.54 (1.27–5.10)*
 Other Candida spp 0.85 1.10 1.29 (.75–2.22) 3.00 4.22 1.41 (.90–2.19)
45–64 years
  C. albicans 6.28 8.49 1.35 (.99–1.83) 12.89 11.80 0.92 (.69–1.21)
  C. glabrata 1.38 15.06 10.89 (5.91–20.06)* 9.09 12.27 1.35 (.99–1.85)
  C. parapsilosis 1.26 3.44 2.74 (1.42–5.26)* 5.19 5.11 1.35 (.83–2.19)
 Other Candida spp 1.88 3.25 1.73 (1.00–2.98)* 6.28 9.57 1.52 (1.05–2.21)*
≥65 years
  C. albicans 14.81 22.58 1.52 (1.13–2.06)* 30.13 24.27 0.81 (.63–1.03)
  C. glabrata 4.47 28.61 6.40 (3.83–10.70)* 20.52 23.18 1.13 (.85–1.50)






















(95% CI)Species by Age Group 1992–1993 2008–2011 1998–2000 2008–2011
  C. parapsilosis 3.63 8.81 2.42 (1.35–4.36)* 5.19 9.96 1.92 (1.15–3.20)*
 Other Candida spp 6.43 10.02 1.56 (.99–2.46) 11.43 12.68 1.11 (.76–1.62)
Abbreviation: CI, confidence interval.
*
Significant at P < .05.
a
Per 100 000 person-years.
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